10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols
Key Takeaways
- One unit of Packed Red Blood Cells (PRBCs, ~300 mL, Hct 55–65%) increases an adult hemoglobin by ~1.0 g/dL and hematocrit by ~3%; restrictive transfusion triggers (Hb <7.0 g/dL in stable/critically ill, Hb <8.0 g/dL in orthopedic/cardiovascular surgery, and Hb <8.0–9.0 g/dL in active acute coronary syndromes) optimize clinical outcomes and minimize transfusion-related risks.
- Stored PRBCs develop progressive biochemical 'storage lesions' characterized by depletion of 2,3-DPG (shifting the oxyhemoglobin dissociation curve to the left and impeding tissue oxygen unloading), depletion of ATP, progressive acidosis (pH <6.5), and extracellular potassium leakage (up to 20–30+ mEq/L by day 35–42).
- Specific component dosing and triggers: FFP (10–15 mL/kg, triggers: INR >1.5–2.0 or PT >1.5x control with active bleeding), Platelets (1 apheresis unit raises count by 30,000–50,000/µL; triggers: <50,000/µL for major surgery, <100,000/µL for neurosurgery/cardiac surgery), and Cryoprecipitate (10-unit pool supplies 1.5–2.5 g fibrinogen, raising levels by 50–70 mg/dL; trigger: fibrinogen <150–200 mg/dL).
- Massive Transfusion Protocol (MTP)—activated when >10 units PRBCs/24h or >4 units/1h are required—mandates a balanced 1:1:1 ratio (PRBCs : FFP : Platelets) to recreate whole blood clotting properties and combat the lethal triad of hypothermia, acidosis, and coagulopathy.
- Transfusion-Related Acute Lung Injury (TRALI)—the leading cause of transfusion-related mortality—is an antibody-mediated (anti-HLA/HNA) non-cardiogenic pulmonary edema with normal CVP/BNP presenting within 6 hours, whereas Transfusion-Associated Circulatory Overload (TACO) is hydrostatic pulmonary edema characterized by hypervolemia, hypertension, elevated CVP/BNP, and rapid response to diuresis.
Last updated: August 2026
10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols
Allogeneic blood transfusion is a lifesaving intervention that carries significant immunological, infectious, and metabolic risks. In modern anesthetic practice, hemotherapy has evolved from empirical whole-blood administration to targeted, component-specific replacement guided by evidence-based transfusion triggers, restrictive guidelines, and structured massive transfusion protocols.
1. Blood Component Characteristics, Dosing & Evidence-Based Triggers
Whole blood is fractionated into individual therapeutic components: Packed Red Blood Cells (PRBCs), Fresh Frozen Plasma (FFP), Platelets, and Cryoprecipitate.
+-------------------------------------------------------------------------+
| BLOOD COMPONENT SUMMARY & EXPECTED YIELD |
+-------------------+--------------------+--------------------------------+
| Blood Component | Unit Volume / Hct | Expected Clinical Yield |
+-------------------+--------------------+--------------------------------+
| PRBCs | ~300 mL (Hct 60%) | +1.0 g/dL Hb / +3% Hct per unit|
| FFP | 200 - 250 mL | +20 - 30% factor levels (10-15)|
| Platelets (Aph) | 250 - 300 mL | +30,000 - 50,000/uL per unit |
| Cryoprecipitate | 10-15 mL/unit pool | +50 - 70 mg/dL fibrinogen (10u)|
+-------------------+--------------------+--------------------------------+
Detailed Component Specifications
1. Packed Red Blood Cells (PRBCs)
- Composition: Centrifuged from whole blood; volume $\approx 250 - 350\text{ mL}$ with a Hematocrit of $55 - 65%$ (in additive solution AS-1, AS-3, or AS-5). Stored at $1 - 6^\circ\text{C}$ with a shelf-life of 35 days (CPDA-1) or 42 days (additive solutions).
- Expected Yield: In a 70-kg adult, 1 unit of PRBCs increases Hemoglobin by $\approx 1.0\text{ g/dL}$ and Hematocrit by $\approx 3%$.
- Transfusion Triggers (AABB & ASA Practice Guidelines):
- Restrictive Threshold ($Hb < 7.0\text{ g/dL}$): Indicated for hospitalized, hemodynamically stable adult patients and critically ill ICU patients (supported by the seminal TRICC trial).
- Intermediate Threshold ($Hb < 8.0\text{ g/dL}$): Indicated for patients undergoing major orthopedic surgery, cardiac surgery, or those with preexisting stable cardiovascular disease (FOCUS trial).
- Higher Threshold ($Hb < 8.0 - 9.0\text{ g/dL}$ or $<10.0\text{ g/dL}$): Indicated for patients with Acute Coronary Syndrome (ACS), active ongoing myocardial ischemia, severe traumatic brain injury, or inadequate global oxygen delivery ($ScvO_2 < 70%$).
2. Fresh Frozen Plasma (FFP)
- Composition: Prepared from centrifuged whole blood and frozen at $-18^\circ\text{C}$ or colder within 8 hours of collection (shelf-life 1 year). Volume is $\approx 200 - 250\text{ mL}$. Contains normal plasma concentrations of all soluble clotting factors ($\approx 1\text{ unit/mL}$ of all factors) and $2 - 4\text{ g/L}$ fibrinogen.
- Dosing: $10 - 15\text{ mL/kg}$ (typically 3–4 units in an adult), which raises coagulation factor levels by $20 - 30%$ (the minimum hemostatic threshold for most factors is $20-30%$ of normal).
- Transfusion Triggers: Active microvascular bleeding in patients with documented coagulopathy ($\text{INR} > 1.5 - 2.0$ or $\text{PT/aPTT} > 1.5\times\text{ control}$), massive transfusion protocols (MTP), urgent reversal of warfarin when prothrombin complex concentrate (4F-PCC) is unavailable, or antithrombin III deficiency during heparin resistance.
- Contraindications: Should never be used solely for simple volume expansion or nutritional support.
3. Platelets (Single-Donor Apheresis vs. Pooled Random-Donor)
- Composition: 1 apheresis unit (collected from a single donor) contains $\ge 3.0 \times 10^{11}$ platelets, which is equivalent to 4–6 pooled random-donor whole-blood platelet units. Volume is $\approx 250 - 300\text{ mL}$.
- Storage: Stored at $20 - 24^\circ\text{C}$ (room temperature) with continuous gentle agitation (shelf-life only 5–7 days). Crucial NCE Point: Because they are stored at room temperature, platelets have the highest incidence of bacterial contamination and septic transfusion reactions among all blood products.
- Expected Yield: 1 apheresis unit increases platelet count by $30,000 - 50,000/\mu\text{L}$ in a 70-kg adult.
- Transfusion Triggers:
- $< 50,000/\mu\text{L}$: Active bleeding, major noncardiac surgery, or invasive procedures (lumbar puncture, neuraxial anesthesia, central venous catheterization).
- $< 100,000/\mu\text{L}$: Neurosurgery (intracranial/spinal), posterior eye surgery, or ongoing microvascular bleeding post-cardiopulmonary bypass (CPB).
- $< 10,000 - 20,000/\mu\text{L}$: Prophylactic transfusion in non-bleeding medical/oncology patients.
- Platelet Dysfunction: Irrespective of absolute count in patients on antiplatelet agents (aspirin, clopidogrel, ticagrelor) or with uremic thrombocytopathy who exhibit active microvascular bleeding.
4. Cryoprecipitate
- Composition: The cold-insoluble precipitate recovered when FFP is thawed at $1 - 6^\circ\text{C}$. Volume is small ($\approx 10 - 15\text{ mL}$ per single unit; usually dispensed as a 10-unit pooled bag totaling $100-150\text{ mL}$).
- High-Yield Contents per Unit:
- Fibrinogen: $150 - 250\text{ mg}$
- Factor VIII: $80 - 100\text{ IU}$
- von Willebrand Factor (vWF): $40 - 70%$ of original plasma
- Factor XIII: $40 - 60\text{ IU}$
- Fibronectin
- Expected Yield: A standard 10-unit pool delivers $1.5 - 2.5\text{ g}$ of fibrinogen, raising serum fibrinogen by $50 - 70\text{ mg/dL}$ in a 70-kg adult.
- Transfusion Triggers: Bleeding patients with hypofibrinogenemia ($<150 - 200\text{ mg/dL}$) in trauma, massive transfusion, cardiac surgery, postpartum hemorrhage, or DIC; dysfibrinogenemia; or von Willebrand disease / Hemophilia A when specific recombinant factor concentrates are unavailable.
Allowable Blood Loss (ABL) Calculation
- Average Blood Volumes by Population: Premature neonate: $90-100\text{ mL/kg}$; Full-term neonate: $85-90\text{ mL/kg}$; Infant ($3-12\text{ mo}$): $75-80\text{ mL/kg}$; Adult male: $70-75\text{ mL/kg}$; Adult female: $65\text{ mL/kg}$; Obese adult: calculate based on ideal body weight $+ 20%$.
- Example: An 80-kg male with initial Hct of $42%$ has a target Hct of $28%$.
2. PRBC Storage Lesions & Metabolic Consequences
As packed red blood cells are stored at $1 - 6^\circ\text{C}$ over their 35–42 day lifespan, they undergo progressive structural, biochemical, and functional degradation collectively termed the RBC storage lesion.
+-------------------------------------------------------------------------+
| THE PRBC STORAGE LESION |
+------------------------------------+------------------------------------+
| BIOCHEMICAL DEGENERATION | PHYSIOLOGICAL CONSEQUENCE |
+------------------------------------+------------------------------------+
| Depletion of 2,3-DPG | Shifts oxyhemoglobin curve LEFT |
| | (decreases P50, impairs O2 delivery|
| Depletion of ATP | Loss of biconcave shape, sludging |
| Acidosis (pH drops to <6.5) | Worsens systemic acidosis |
| Potassium leakage (>20-30 mEq/L) | Risk of severe hyperkalemia |
| Free Hemoglobin / Microparticles | Nitric oxide scavenging, vasospasm |
| Citrate preservative accumulation | Chelation of ionized calcium (Ca2+)|
+------------------------------------+------------------------------------+
Key Biochemical Alterations
- 2,3-Diphosphoglycerate (2,3-DPG) Depletion: Levels of 2,3-DPG fall precipitously within 1–2 weeks of storage. Because 2,3-DPG normally stabilizes deoxyhemoglobin, its absence causes a LEFTWARD shift in the oxyhemoglobin dissociation curve (decreased $P_{50}$ from normal $26.8\text{ mmHg}$ down to $<18\text{ mmHg}$). Transfused red cells hold avidly onto oxygen, impairing tissue oxygen unloading at the microcirculatory capillary bed. (2,3-DPG regenerates in vivo over 12–24 hours post-transfusion).
- ATP Depletion: Loss of ATP inhibits the $Na^+/K^+\text{-ATPase}$ pump, causing cell swelling, loss of the flexible biconcave disk shape (forming rigid echinocytes and spherocytes), and phospholipid vesiculation.
- Extracellular Hyperkalemia: Because the cold temperature halts the $Na^+/K^+$ pump, intracellular potassium leaks down its concentration gradient into the extracellular preservative fluid. Extracellular $[K^+]$ increases from $4\text{ mEq/L}$ on Day 1 to $>20 - 30\text{ mEq/L}$ on Day 35 (and $>50\text{ mEq/L}$ in irradiated units). Rapid infusion can precipitate life-threatening hyperkalemic cardiac arrest.
- Acidosis: Ongoing anaerobic glycolysis by RBCs produces lactic and pyruvic acids, causing unit pH to fall below $6.5$ by the end of shelf life.
3. Massive Transfusion Protocol (MTP) & The Lethal Triad
Massive transfusion is clinically defined as:
- Replacement of $\ge 10\text{ units}$ of PRBCs in 24 hours, OR
- Transfusion of $>4\text{ units}$ of PRBCs in 1 hour with anticipated ongoing need, OR
- Replacement of $>50%$ of total blood volume in 3 hours, OR
- Blood loss exceeding $150\text{ mL/min}$.
+-------------------------------------------------------------------------+
| THE TRAUMA / HEMORRHAGE LETHAL TRIAD |
+--------------------+----------------------------+-----------------------+
| 1. HYPOTHERMIA | 2. ACIDOSIS | 3. COAGULOPATHY |
| - Temp < 35°C | - pH < 7.20 | - Dilutional loss |
| - Enzyme kinetics | - Impairs clotting factor | - Platelet dysfunction|
| drop 10% per 1°C | complex assembly on cell | - Hyperfibrinolysis |
| - Platelet dysfnc | surfaces (VIIa drop 90%) | - Hypocalcemia |
+--------------------+----------------------------+-----------------------+
| ▲ |
| Each leg of the triad exacerbates and accelerates the others |
+-------------------------------------------------------------------------+
Balanced Resuscitation & The 1:1:1 Strategy
Historically, massive hemorrhage was managed with crystalloid boluses followed by unguided PRBC infusions, creating profound dilutional coagulopathy. The PROPPR Trial (Pragmatic Randomized Optimal Platelet and Plasma Ratios) established modern balanced resuscitation:
- Fixed 1:1:1 Ratio: Transfusion of 1 unit of PRBCs : 1 unit of FFP : 1 apheresis unit of Platelets (per 6 PRBCs/FFPs).
- Clinical Rationale: Simulates reconstituted whole blood (producing a Hematocrit of $\approx 30%$, platelet count $>50,000/\mu\text{L}$, and coagulation factor levels $\ge 60%$), minimizing dilutional coagulopathy and significantly reducing early mortality from exsanguination.
4. Metabolic & Electrolyte Complications of Massive Transfusion
| Complication | Pathophysiologic Mechanism | Clinical Manifestations | Anesthetic Management |
|---|---|---|---|
| Citrate Toxicity & Hypocalcemia | Banked blood contains sodium citrate ($1.66\text{ g/unit}$) to chelate calcium and prevent in-vitro clotting. Rapid transfusion ($>1\text{ unit/5 min}$) or impaired hepatic metabolism (shock, hypothermia, cirrhosis) causes citrate accumulation, chelating recipient ionized $Ca^{2+}$. | Narrow pulse pressure, hypotension, decreased cardiac contractility, elevated CVP, prolonged QTc interval, tetany, laryngospasm, ventricular arrhythmias | Administer Calcium Chloride ($1\text{ g IV}$, delivers $270\text{ mg}$ elemental $Ca^{2+}$) or Calcium Gluconate ($3\text{ g IV}$, delivers $270\text{ mg}$ elemental $Ca^{2+}$). Maintain ionized $Ca^{2+} > 1.0 - 1.12\text{ mmol/L}$. |
| Hyperkalemia | Hemolysis and progressive potassium leakage from stored PRBCs (up to $30\text{ mEq/L}$ in supernatant). Rapid infusion into central circulation overwhelms renal excretion. | Peaked T waves, PR interval prolongation, widening QRS complex, loss of P wave, sine-wave pattern, asystole/VF | Administer $1\text{ g}$ Calcium Chloride to stabilize cardiac membrane; push Regular Insulin 10 units $+$ $50\text{ mL } D_{50}W$; hyperventilate (each $0.1\uparrow\text{ pH}$ lowers $[K^+]$ by $\approx 0.5\text{ mEq/L}$); albuterol nebulizer. |
| Hypothermia | Rapid infusion of cold blood products ($4^\circ\text{C}$) and room-temperature fluids into an open cavity under general anesthesia. | Core body temperature $<35^\circ\text{C}$; coagulopathy (10% drop in enzyme cascade velocity per $1^\circ\text{C}$ drop); shivering on emergence ($400%$ increase in $VO_2$). | Utilize high-flow rapid infusers with inline warmers (e.g., Belmont, Level 1 at $41^\circ\text{C}$); forced-air warming blankets; warm ambient OR temperature ($>24^\circ\text{C}$). |
| Acid-Base Swings | Early Phase: Metabolic acidosis from lactic acid and acidic preservatives in stored blood.<br/>Delayed Phase: Metabolic alkalosis as hepatic metabolism converts each molecule of citrate into 3 molecules of bicarbonate ($HCO_3^-$). | Early: myocardial depression.<br/>Delayed: hypokalemia, compensatory hypoventilation, left-shifted oxyhemoglobin curve. | Serial arterial blood gas (ABG) monitoring; avoid over-correcting early acidosis with sodium bicarbonate. |
5. Adverse Transfusion Reactions & Pulmonary Complications
Adverse reactions range from mild febrile episodes to life-threatening pulmonary collapse and acute intravascular hemolysis.
TRALI vs. TACO: Differential Diagnosis (High-Yield NCE Topic)
| Clinical Feature | Transfusion-Related Acute Lung Injury (TRALI) | Transfusion-Associated Circulatory Overload (TACO) |
|---|---|---|
| Primary Mechanism | Immune-mediated: Donor anti-HLA or anti-human neutrophil antigen (anti-HNA) antibodies activate recipient neutrophils in pulmonary capillaries $\rightarrow$ endothelial damage and non-cardiogenic capillary leak. | Hydrostatic volume overload: Excessive fluid volume or rapid infusion rate exceeding cardiac and renal excretory capacity $\rightarrow$ hydrostatic cardiogenic pulmonary edema. |
| Leading Blood Source | High-plasma products (FFP, Platelets) from multiparous female donors (alloimmunized during pregnancy). | Any blood product or crystalloid/colloid infusion; common in elderly, renal failure, CHF. |
| Timing | Within 6 hours of transfusion completion (often within 1–2 hours). | Within 6 hours of transfusion (often during or immediately post-infusion). |
| Hemodynamics | Hypotension or normal blood pressure; tachycardia. | Hypertension (widened pulse pressure); tachycardia. |
| CVP / PAOP | Normal or LOW (non-cardiogenic; CVP $<10\text{ mmHg}$, PAOP $<18\text{ mmHg}$). | ELEVATED (cardiogenic; CVP $>15\text{ mmHg}$, PAOP $>18\text{ mmHg}$). |
| BNP / NT-proBNP | Normal or minimally elevated. | Markedly elevated ($>1.5\times$ pre-transfusion baseline or $>1,200\text{ pg/mL}$). |
| Body Temperature | Fever / Hypothermia commonly present ($>1^\circ\text{C}$ rise). | Temperature typically normal. |
| Edema Fluid Analysis | Exudative: High protein content (fluid/plasma protein ratio $>0.7$). | Transudative: Low protein content (fluid/plasma protein ratio $<0.5$). |
| Echocardiogram | Normal LV systolic function; hyperdynamic. | LV systolic/diastolic dysfunction, elevated filling pressures. |
| Response to Diuretics | Minimal / Unresponsive (may worsen hypotension). | Rapid, dramatic improvement with IV loop diuretics (furosemide). |
| Management | Lung-protective ventilation (low $V_t$ 6 mL/kg, PEEP), hemodynamic support with fluids/vasopressors; notify blood bank to quarantine donor products. | Stop/slow transfusion, sit patient upright, administer supplemental $O_2$/CPAP, give IV Furosemide ($20 - 40\text{ mg}$). |
Acute Hemolytic Transfusion Reaction (AHTR)
- Etiology: Intravascular destruction of transfused RBCs caused by ABO incompatibility (almost universally due to clerical/administrative misidentification of patient or blood sample). Preformed recipient IgM antibodies bind donor RBC surface antigens, activating the full complement cascade ($C5b-9$ membrane attack complex) and triggering massive intravascular hemolysis.
- Classic Triad Under General Anesthesia:
- Unexplained, Refractory Hypotension
- Hemoglobinuria (Burgundy / Dark "Cola-Colored" Urine)
- Diffuse Microvascular Oozing in the Surgical Field (DIC)
- Immediate Anesthetic Management Protocol:
- STOP THE TRANSFUSION IMMEDIATELY. Disconnect tubing and save all blood bags and tubing to return to the blood bank.
- Re-check patient identification wristband, blood product label, and compatibility tags.
- Maintain vigorous renal perfusion: Administer IV crystalloid fluids to maintain urine output $\ge 1 - 2\text{ mL/kg/hr}$ to prevent precipitation of toxic acid hematin in renal tubules.
- Administer osmotic diuretics (Mannitol $12.5 - 25\text{ g IV}$) and loop diuretics (Furosemide $20 - 40\text{ mg IV}$).
- Alkalinize the urine by infusing Sodium Bicarbonate ($40 - 70\text{ mEq/L}$) to maintain urine $pH > 7.0$ (inhibits acid hematin crystallization).
- Send repeat blood samples (lavender and red top tubes) and urine samples to the blood bank for direct antiglobulin test (DAT / Coombs test), repeat crossmatching, plasma free hemoglobin, and serum haptoglobin.
- Support systemic blood pressure and inotropy with vasopressors.
Loading diagram...
Test Your Knowledge
Two hours after receiving 2 units of Fresh Frozen Plasma and 1 unit of PRBCs for coagulopathy following an uneventful total hip arthroplasty, a 68-year-old female develops acute dyspnea, tachypnea, and hypoxemia (SpO2 84% on room air). Physical exam reveals bilateral coarse crackles, blood pressure 82/46 mmHg, heart rate 124 bpm, and a temperature of 38.6°C. Chest radiography demonstrates diffuse bilateral alveolar infiltrates without cardiomegaly. A central venous catheter reveals a CVP of 4 mmHg, and serum BNP is 85 pg/mL (normal <100 pg/mL). What is the most likely diagnosis?
A
B
C
D
Test Your Knowledge
A 32-year-old trauma patient in hemorrhagic shock has received 12 units of PRBCs, 10 units of FFP, and 2 apheresis units of platelets over the past 90 minutes. The patient continues to exhibit diffuse microvascular oozing across the surgical field. A laboratory panel reveals: Platelets 85,000/µL, INR 1.3, aPTT 34 seconds, and Fibrinogen 80 mg/dL. Which blood product is most specifically indicated to correct this patient's coagulopathy?
A
B
C
D
Test Your Knowledge
During a lumbar spinal fusion under general endotracheal anesthesia, a 55-year-old male is transfused 1 unit of PRBCs. Thirty minutes into the transfusion, the CRNA notices unexplained refractory hypotension (blood pressure drops from 120/75 to 68/40 mmHg) unresponsive to phenylephrine boluses, diffuse dark burgundy-colored urine in the Foley bag, and sudden microvascular oozing from the surgical wound. What is the immediate priority intervention?
A
B
C
D